Lipocine Q2 net loss widens as revenue declines

Lipocine

04/08/2026 13:20

Overview
Specialty pharmaceutical firm's Q2 royalty revenue rose, but overall revenue declined yr/yr
Net loss for Q2 widened compared to prior year quarter
Company continues clinical trials and business development for pipeline products

Outlook
Company to meet with FDA in Q3 2026 on LPCN 1154 development path
Lipocine has initiated a new placebo-controlled clinical trial for LPCN 1154 in PPD
Company may initiate Phase 2 studies for LPCN 2201 in MDD and LPCN 2203 in essential tremor

Result Drivers
ROYALTY REVENUE - Q2 royalty revenue from TLANDO increased to $190,000 from $123,000 in the prior-year period
NO LICENSE REVENUE - No license revenue recognized in Q2 2026, compared to $500,000 in Q2 2025
R&D SPENDING - Research and development expenses remained high, driven by costs related to the LPCN 1154 Phase 3 study and increased personnel expense

Company press release: ID:nPnbmkmnfa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.32
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Lipocine Inc is $6.00, about 184.4% above its August 3 closing price of $2.11

Reuters Recommended Reads
Aug 3 - Stoke Therapeutics Q2 revenue falls 33% on lower collaboration, licensing income
Aug 4 - Palvella Therapeutics Q2 net loss widens on higher expenses
Aug 3 - Supernus, Indivior merge to strengthen neuroscience drug portfolio

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)